📰 Zeneca Data News
Page 2 - Zeneca Data News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Zeneca Data. Real-time updates on events, politics, business and more.
April 21, 2022
Detailed results from the PROVENT Phase III pre-exposure prophylaxis trial showed that AstraZeneca’s Evusheld, formerly AZD7442, reduced the risk of...
April 20, 2022
21.04.2022 - Detailed results from the PROVENT Phase III pre-exposure prophylaxis (prevention) trial showed that AstraZeneca’s EVUSHELD (tixagevimab and cilgavimab), formerly AZD7442, reduced the risk of developing symptomatic COVID-19 by 77% in the primary ...
March 28, 2022
AstraZeneca's Evusheld (tixagevimab co-packaged with cilgavimab), a long-acting antibody combination, has been granted marketing authorisation in the...
March 24, 2022
Investegate announcements from AstraZeneca PLC, Evusheld Positive EU CHMP Opinion
March 14, 2022
Investegate announcements from AstraZeneca PLC, Update on US review of Fasenra in nasal polyps
December 16, 2020
Search jobs 16-Dec-2020 First patients dosed in Phase III trials evaluating Fasenra in hypereosinophilic syndrome, eosinophilic esophagitis and eosinophilic granulomatosis with polyangiitis New clinical trial also announced for Fasenra in eosinophilic gastritis/eosinophilic gastroenteritis The first patients have been dosed in Fasenra (benralizumab) Phase III trials in three rare eosinophilic diseases: hypereosinophilic syndrome (HES), eosinop...